Association of cardiac biomarkers with long-term cardiovascular events in a community cohort.

IF 2 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biomarkers Pub Date : 2024-06-01 Epub Date: 2024-04-26 DOI:10.1080/1354750X.2024.2335245

Robert A Churchill, Benjamin R Gochanour, Christopher G Scott, Vlad C Vasile, Richard J Rodeheffer, Jeffrey W Meeusen, Allan S Jaffe

{"title":"Association of cardiac biomarkers with long-term cardiovascular events in a community cohort.","authors":"Robert A Churchill, Benjamin R Gochanour, Christopher G Scott, Vlad C Vasile, Richard J Rodeheffer, Jeffrey W Meeusen, Allan S Jaffe","doi":"10.1080/1354750X.2024.2335245","DOIUrl":null,"url":null,"abstract":"Materials and methods: The study assessed major adverse cardiac events (MACE) (myocardial infarction, coronary artery bypass graft, percutaneous intervention, stroke, and death. Cox proportional hazards models assessed apolipoprotein AI (ApoA1), apolipoprotein B (ApoB), ceramide score, cystatin C, galectin-3 (Gal3), LDL-C, Non-HDL-C, total cholesterol (TC), N-terminal B-type natriuretic peptide (NT proBNP), high-sensitivity cardiac troponin (HscTnI) and soluble interleukin 1 receptor-like 1. In adjusted models, Ceramide score was defined by from N-palmitoyl-sphingosine [Cer(16:0)], N-stearoyl-sphingosine [Cer(18:0)], N-nervonoyl-sphingosine [Cer(24:1)] and N-lignoceroyl-sphingosine [Cer(24:0)]. Multi-biomarker models were compared with C-statistics and Integrated Discrimination Index (IDI).Results: A total of 1131 patients were included. Adjusted NT proBNP per 1 SD resulted in a 31% increased risk of MACE/death (HR = 1.31) and a 31% increased risk for stroke/MI (HR = 1.31). Adjusted Ceramide per 1 SD showed a 13% increased risk of MACE/death (HR = 1.13) and a 29% increased risk for stroke/MI (HR = 1.29). These markers added to clinical factors for both MACE/death (p = 0.003) and stroke/MI (p = 0.034). HscTnI was not a predictor of outcomes when added to the models.Discussion: Ceramide score and NT proBNP improve the prediction of MACE and stroke/MI in a community primary prevention cohort.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"161-170"},"PeriodicalIF":2.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2024.2335245","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Materials and methods: The study assessed major adverse cardiac events (MACE) (myocardial infarction, coronary artery bypass graft, percutaneous intervention, stroke, and death. Cox proportional hazards models assessed apolipoprotein AI (ApoA1), apolipoprotein B (ApoB), ceramide score, cystatin C, galectin-3 (Gal3), LDL-C, Non-HDL-C, total cholesterol (TC), N-terminal B-type natriuretic peptide (NT proBNP), high-sensitivity cardiac troponin (HscTnI) and soluble interleukin 1 receptor-like 1. In adjusted models, Ceramide score was defined by from N-palmitoyl-sphingosine [Cer(16:0)], N-stearoyl-sphingosine [Cer(18:0)], N-nervonoyl-sphingosine [Cer(24:1)] and N-lignoceroyl-sphingosine [Cer(24:0)]. Multi-biomarker models were compared with C-statistics and Integrated Discrimination Index (IDI).

Results: A total of 1131 patients were included. Adjusted NT proBNP per 1 SD resulted in a 31% increased risk of MACE/death (HR = 1.31) and a 31% increased risk for stroke/MI (HR = 1.31). Adjusted Ceramide per 1 SD showed a 13% increased risk of MACE/death (HR = 1.13) and a 29% increased risk for stroke/MI (HR = 1.29). These markers added to clinical factors for both MACE/death (p = 0.003) and stroke/MI (p = 0.034). HscTnI was not a predictor of outcomes when added to the models.

Discussion: Ceramide score and NT proBNP improve the prediction of MACE and stroke/MI in a community primary prevention cohort.

查看原文本刊更多论文

社区队列中的心脏生物标志物与长期心血管事件的关系。

材料与方法：研究评估了主要心脏不良事件（MACE）（心肌梗死、冠状动脉旁路移植术、经皮介入治疗、中风和死亡）。Cox 比例危险度模型评估了载脂蛋白 AI（载脂蛋白 A1）、载脂蛋白 B（载脂蛋白 B）、神经酰胺评分、胱抑素 C、galectin-3（Gal3）、低密度脂蛋白胆固醇（LDL-C）、非高密度脂蛋白胆固醇（Non-HDL-C）、总胆固醇（TC）、N 端 B 型钠尿肽（NT proBNP）、高敏心肌肌钙蛋白（HscTnI）和可溶性白细胞介素 1 受体样 1。在调整模型中，神经酰胺得分由 N-棕榈酰肌球蛋白[Cer(16:0)]、N-硬脂酰肌球蛋白[Cer(18:0)]、N-神经酰肌球蛋白[Cer(24:1)]和 N-木质素酰肌球蛋白[Cer(24:0)]定义。用C统计量和综合判别指数（IDI）对多生物标志物模型进行比较：结果：共纳入 1131 例患者。调整后的每 1 SD NT proBNP 使 MACE/死亡风险增加 31%（HR = 1.31），中风/MI 风险增加 31%（HR = 1.31）。调整后的神经酰胺每 1 SD 显示 MACE/死亡风险增加 13%（HR = 1.13），中风/MI 风险增加 29%（HR = 1.29）。这些标记物增加了MACE/死亡（P = 0.003）和卒中/心肌梗死（P = 0.034）的临床因素。当加入模型时，HscTnI 并非预测结果的指标：讨论：神经酰胺评分和NT proBNP可改善社区一级预防队列中MACE和卒中/MI的预测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers 医学-毒理学

CiteScore

5.00

自引率

3.80%

发文量

140

审稿时长

3 months

期刊介绍： The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.